Santen Sirolimus drug secures FDA orphan drug status Pharmaceutical Business Review The US FDA has granted orphan drug status for Santen's sirolimus (DE-109, rapamycin) to treat chronic/refractory anterior non-infectious uveitis, non-infectious intermediate uveitis, non-infectious panuveitis, and non-infectious uveitis affecting the ... Santen Announces FDA Orphan Drug Status for Sirolimus (DE-109) |
